Diagnosis Articles

?️ Articles on positive diagnosis of NASH/NAFLD; there should be hepatic steatosis by imaging or histology or no significant alcohol consumption.

NAFLD: no liver biopsy in 2/3 patients of a real-world cohort

Much of the current data on NAFLD are derived from biopsy-based studies that may introduce ascertainment and selection bias. Selection of patients for liver biopsy has implications for clinical practice and the reported epidemiology of NAFLD. The aim of this study was to determine patient factors predictive....
Read MoreNAFLD: no liver biopsy in 2/3 patients of a real-world cohort

NAFLD in patients with schizophrenia: early detection should be conducted

ndividuals with schizophrenia have high levels of medical comorbidity and cardiovascular risk factors. Patients with schizophrenia should receive regular monitoring and adequate treatment of cardio-metabolic risk factors. Nevertheless, little is known regarding NAFLD in patients with schizophrenia. A. Koreki et al. analysed the medical...
Read MoreNAFLD in patients with schizophrenia: early detection should be conducted

Assessment of imaging modalities against liver biopsy

Multiparametric MRI is a promising technique to assess hepatic steatosis, inflammation, and fibrosis, potentially enabling non-invasive identification of individuals with active and advanced stages of NAFLD. The aim of the current proof-of-principle study by M. A. Troelstra et al. (Amsterdam University Medical Centres, The ...
Read MoreAssessment of imaging modalities against liver biopsy

NAFLD: a year in review

he field of NAFLD and its progressive form, NASH, has, despite the challenges of the COVID-19 pandemic, continued to rapidly evolve in 2020. There have been substantial advances in NAFLD mechanisms, diagnostics, and treatment. Key developments include the identification of a multiparametric cellular and tissue signature to define disease progression...
Read MoreNAFLD: a year in review

Cost-effectiveness of screening for NAFLD in patients with T2D

The authors hypothesized that screening for NAFLD in type 2 diabetes (T2D) patients, starting with ultrasound (US) and alanine aminotransferase (ALT) or aspartate aminotransferase (AST), followed with non-invasive testing for fibrosis to detect those most likely to have fibrosis stage ≥F2, is more cost effective than not screening this population...
Read MoreCost-effectiveness of screening for NAFLD in patients with T2D

A Cross-Sectional Study of the Public Health Response to NAFLD in Europe

In 2018 and 2019, NAFLD experts in 29 European countries completed an English-language survey on policies, guidelines, awareness, monitoring, diagnosis and clinical assessment in their country. The data were compiled, quality checked against existing official documents and reported descriptively...

Read MoreA Cross-Sectional Study of the Public Health Response to NAFLD in Europe